Evidence mapping of clinical research on traditional Chinese medicine in treatment of idiopathic pulmonary fibrosis.
10.19540/j.cnki.cjcmm.20240821.501
- Author:
Li-Li XU
1
;
Dan-Yang ZANG
1
;
Shu-Guang YANG
1
;
Ning-Xia YU
1
;
Xue-Qing YU
1
Author Information
1. National Regional Traditional Chinese Medicine (Lung Disease) Diagnosis and Treatment Center,the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450000, China the First Clinical Medical School, Henan University of Chinese Medicine Zhengzhou 450000, China.
- Publication Type:English Abstract
- Keywords:
evidence map;
idiopathic pulmonary fibrosis;
methodology;
traditional Chinese medicine
- MeSH:
Humans;
Idiopathic Pulmonary Fibrosis/drug therapy*;
Drugs, Chinese Herbal/therapeutic use*;
Medicine, Chinese Traditional;
Randomized Controlled Trials as Topic
- From:
China Journal of Chinese Materia Medica
2024;49(24):6803-6812
- CountryChina
- Language:Chinese
-
Abstract:
This study systematically retrieved the clinical studies in the treatment of idiopathic pulmonary fibrosis(IPF) with traditional Chinese medicine(TCM) and employed evidence mapping to summarize the overall research status and deficiencies of TCM in treating IPF. CNKI, VIP, SinoMed, Wanfang, PubMed, Web of Science, Cochrane Library, and EMbase were searched for the relevant studies published from inception to February 20, 2024. The distribution characteristics of the evidence were analyzed and presented through charts combined with words. A total of 323 studies were included, including 295 randomized controlled trials(RCTs) and 28 Meta-analysis. The number of publications in this field rose with fluctuations, yet the proportion of core papers was low, and the research lacked the attention of foreign researchers. There were scant cross-regional collaboration between researchers and insufficient attention from relevant departments. The included RCT generally had low quality, with small sample sizes, short treatment courses, and insufficient attention to acute exacerbation and complications of IPF. In addition, few studies employed TCM alone, and the TCM syndromes remained to be standardized. A considerable number of outcome indicators were involved in the publications, while the majority of them failed to emphasize the disparity between primary and secondary outcome indicators. There were diverse reference standards for the comprehensive indicators among the outcome indicators, and insufficient attention was paid to long-term prognosis and health economic indicators. The included Meta-analysis concluded that TCM had potential clinical efficacy in treating IPF. However, the methodological credibility grading and the GRADE grading results of outcome indicators were low. The results suggested that TCM demonstrated certain advantages in the treatment of IPF, while the quality of the included studies was not high. In the future, clinical research protocols should be standardized and registered. Multicenter, large-sample, and follow-up clinical studies should be conducted. The research reports should refer to relevant reporting standards to improve the quality and generate high-level evidence, thus providing a reference for the clinical application of TCM in the treatment of IPF.
